Disciplined offerings.
Verified impact.
Each GCRC project is structured to surpass the USCIS job-creation minimum while delivering meaningful, community-anchored development in Philadelphia and Southern New Jersey.
Africa Center
Dolakeh Square.
A community-led development serving the African diaspora and Southwest Philadelphia. Co-developed with the African Cultural Alliance of North America (ACANA), the project anchors a long-term cultural and economic corridor in Africatown.
A cornerstone for economic development, cultural celebration, and community resilience.
The $24 million Africa Center is the first phase of the Dolakeh Square in Africatown initiative — designed to serve as a long-term anchor for economic growth and cultural identity along Chester Avenue.
ACANA — the African Cultural Alliance of North America — is a Community Development Corporation operating since 2000, dedicated to revitalizing commercial corridors in Southwest Philadelphia and serving the African diaspora.
of North America
Crane Chinatown
Eastern Tower.
GCRC's flagship real estate development — a transformative 20-story mixed-use tower rising in Philadelphia's Chinatown North neighborhood. Co-developed by PCDC and JNA Capital, the project converges community vision, strategic investment, and economic opportunity.
A landmark convergence of community vision and capital discipline.
Crane Chinatown — the Eastern Tower Community Center — is GCRC's inaugural project, designed to deliver significant community impact while meeting the rigorous job-creation and economic requirements of the EB-5 program.
Co-developed by the Philadelphia Chinatown Development Corporation (PCDC) and JNA Capital, the project sits at 10th & Vine Streets, anchoring Philadelphia's Chinatown North neighborhood with new residential, community, retail, and gym space.
The project secured 16 EB-5 investors and $8.8M in EB-5 capital investment to date, with approval for up to 66 investors and $33M in total EB-5 capital.
Chinatown North, Philadelphia
Philadelphia Chinatown Development Corp.
$800K EB-5 minimum applicable
EB5 Life Sciences LP
Ocugen · Philadelphia.
EB5 Life Sciences LP is GCRC's pioneering life sciences investment fund — the first in the EB5 industry to channel foreign investor capital into clinical-stage biopharmaceutical companies.
Advancing clinical-stage biopharmaceutical innovation.
EB5 Life Sciences LP is GCRC's pioneering life sciences investment fund — the first in the EB5 industry to channel foreign investor capital into clinical-stage biopharmaceutical companies.
The fund's flagship portfolio company, Ocugen, Inc. (Nasdaq: OCGN), develops cutting-edge gene therapies and biologics for sight-threatening eye diseases, with programs targeting retinal degeneration, macular degeneration, and other conditions with significant unmet need.
A second portfolio company, Mainline Biosciences LLC, is advancing novel peptide compounds for cancer treatment, including selective CXCR4 antagonists targeting lung and breast cancer.
Review the offering
documents in detail.
Qualified investors and their advisors may request the confidential offering memorandum, economic study, and project diligence package directly from GCRC.
Investment involves risk, including potential loss of principal. Past performance does not guarantee future results. This is not an offer to sell securities. Prospective investors should conduct independent due diligence and consult with their own legal, financial, and tax advisors.
